IRWD logo

IRWD
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A

2,643
Mkt Cap
$748.44M
Volume
247,999.00
52W High
$5.78
52W Low
$0.5271
PE Ratio
38.09
IRWD Fundamentals
Price
$4.66
Prev Close
$4.59
Open
$4.64
50D MA
$3.69
Beta
0.84
Avg. Volume
1.72M
EPS (Annual)
$0.1474
P/B
-2.86
Rev/Employee
$2.96M
$931.60
Loading...
Loading...
News
all
press releases
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, presented...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its first quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 7, 2026...
Business Wire·5d ago
News Placeholder
Ironwood Pharmaceuticals (IRWD) Projected to Post Earnings on Wednesday
Ironwood Pharmaceuticals (NASDAQ:IRWD) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-ironwood-pharmaceuticals-inc-stock...
MarketBeat·6d ago
News Placeholder
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 7.3% - Here's What Happened
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 7.3% Higher - What's Next...
MarketBeat·7d ago
News Placeholder
Zacks Research Has Bearish Estimate for IRWD Q2 Earnings
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research cut their Q2 2026 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on...
MarketBeat·12d ago
News Placeholder
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week 2026
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced...
Business Wire·12d ago
News Placeholder
Zacks Research Issues Positive Outlook for IRWD Earnings
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Zacks Research upped their Q4 2026 earnings per share estimates for Ironwood Pharmaceuticals in a note issued to...
MarketBeat·13d ago
News Placeholder
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 6% - Here's What Happened
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 6% - Here's Why...
MarketBeat·14d ago
News Placeholder
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zacks·14d ago
News Placeholder
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Update
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 17,904,692 shares, an increase of 30.7% from the March 15th total of 13,703,587 shares. Based on an...
MarketBeat·19d ago
<
1
2
...
>

Latest IRWD News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.